Fig. 1
Identification of the rs1061632 variant to be associated with LB susceptibility. A Cohorts overview. 1,107 DNA samples from LB patients were available for quality check and imputation, leaving a discovery cohort (n = 506) and a validation cohort (n = 557). Furthermore, cytokine production upon stimulation experiments on PBMCs and whole blood, as well as antibody responses were assessed at baseline and six weeks later. B Manhattan plot of genome wide significant variants associated with susceptibility to LB in the discovery cohort. Chromosomal location is displayed on the x-axis, and -log10 p-values of SNPs on the y-axis. The dashed horizontal line indicates the genome-wide threshold for association (p = 5 × 10–8). The significant variant identified in the discovery cohort (rs1061632, p = 5.38 × 10–8, OR = 0.44), was significant in the validation cohort as well (p = 1.15 × 10–5, OR = 0.54)